PolarityTE, Inc. – NASDAQ:PTE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
PolarityTE stock price monthly change
-5.93%
month
PolarityTE stock price quarterly change
-48.53%
quarter
PolarityTE stock price yearly change
-83.02%
year
PolarityTE key metrics
Market Cap | 1.77M |
Enterprise value | N/A |
P/E | -0.26 |
EV/Sales | -3.64 |
EV/EBITDA | 0.63 |
Price/Sales | 1.74 |
Price/Book | 0.17 |
PEG ratio | N/A |
EPS | 2.90 |
Revenue | N/A |
EBITDA | -21.00M |
Income | 17.40M |
Revenue Q/Q | -100% |
Revenue Y/Y | -98.65% |
Profit margin | -716.95% |
Oper. margin | -2547.91% |
Gross margin | 24.32% |
EBIT margin | -2547.91% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePolarityTE stock price history
PolarityTE stock forecast
PolarityTE financial statements
| Jun 2022 | 73K | 6.59M | 9032.88% |
|---|---|---|---|
| Sep 2022 | 0 | -1.39M | |
| Dec 2022 | 0 | 15.44M | |
| Mar 2023 | 0 | -3.23M |
| Jun 2022 | 28031000 | 7.98M | 28.49% |
|---|---|---|---|
| Sep 2022 | 22145000 | 5.20M | 23.49% |
| Dec 2022 | 22847000 | 6.22M | 27.26% |
| Mar 2023 | 18049000 | 5.62M | 31.18% |
| Jun 2022 | -8.22M | 2.48M | 7.36M |
|---|---|---|---|
| Sep 2022 | -4.03M | 24K | -416K |
| Dec 2022 | -4.29M | 58K | -408K |
| Mar 2023 | -5.08M | 100K | -72K |
PolarityTE alternative data
| Aug 2023 | 42 |
|---|---|
| Sep 2023 | 42 |
| Oct 2023 | 42 |
| Nov 2023 | 42 |
| Dec 2023 | 42 |
| Jan 2024 | 42 |
| Feb 2024 | 42 |
| Mar 2024 | 42 |
| Apr 2024 | 42 |
| May 2024 | 42 |
| Jun 2024 | 42 |
| Jul 2024 | 42 |
PolarityTE other data
14.45%
-6.06%
of PTE is owned by hedge funds
24
-12
516.69K
-139.58K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2021 | 0 | 31037 |
| Aug 2022 | 0 | 23661 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | NOLET CHRIS director | Stock option (right to buy) | 3,078 | $22.5 | $69,255 | ||
Option | NOLET CHRIS director | Common Stock | 36,497 | N/A | N/A | ||
Sale | COHEN PETER A director | Common Stock | 8,555 | $1.28 | $10,950 | ||
Sale | COHEN PETER A director | Common Stock | 15,106 | $1.33 | $20,031 | ||
Sale | SEABURG DAVID B director | Common Stock | 31,037 | $0.55 | $17,194 | ||
Option | SEABURG DAVID B director | Restricted Stock Units | 32,009 | N/A | N/A | ||
Option | SEABURG DAVID B director | Common Stock | 32,009 | N/A | N/A | ||
Sale | HAGUE RICHARD officer: Chf. Ope.. | Common Stock | 10,208 | $0.83 | $8,432 | ||
Sale | HAGUE RICHARD officer: Chf. Ope.. | Common Stock | 12,600 | N/A | N/A | ||
Sale | SEABURG DAVID B officer: Chief Executive Officer | Common Stock | 31,032 | $0.71 | $22,126 |
| Patent |
|---|
Grant Utility: Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells Filling date: 21 May 2021 Issue date: 24 May 2022 |
Grant Filling date: 14 Jul 2017 Issue date: 8 Mar 2022 |
Application Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem Cells Filling date: 21 May 2021 Issue date: 21 Oct 2021 |
Grant Filling date: 19 Oct 2018 Issue date: 11 May 2021 |
Grant Filling date: 30 Nov 2015 Issue date: 23 Feb 2021 |
Grant Filling date: 17 May 2018 Issue date: 1 Sep 2020 |
Application Filling date: 10 Jul 2019 Issue date: 31 Oct 2019 |
Application Filling date: 28 Jan 2019 Issue date: 1 Aug 2019 |
Application Filling date: 28 Jan 2019 Issue date: 1 Aug 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 16 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 30 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 10 Nov 2021 | Q3 2021 Earnings Call Transcript |
-
When is PolarityTE's next earnings date?
Unfortunately, PolarityTE's (PTE) next earnings date is currently unknown.
-
Does PolarityTE pay dividends?
No, PolarityTE does not pay dividends.
-
How much money does PolarityTE make?
PolarityTE has a market capitalization of 1.77M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 91.34% to 814K US dollars.
-
What is PolarityTE's stock symbol?
PolarityTE, Inc. is traded on the NASDAQ under the ticker symbol "PTE".
-
What is PolarityTE's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of PolarityTE?
Shares of PolarityTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are PolarityTE's key executives?
PolarityTE's management team includes the following people:
- Mr. Richard Hague Pres & Chief Executive Officer(age: 65, pay: $649,260)
- Mr. Cameron J. Hoyler Gen. Counsel, Sec. and Executive Vice President of Corporation Devel. & Strategy(age: 41, pay: $623,190)
-
How many employees does PolarityTE have?
As Jul 2024, PolarityTE employs 42 workers.
-
When PolarityTE went public?
PolarityTE, Inc. is publicly traded company for more then 26 years since IPO on 16 Aug 1999.
-
What is PolarityTE's official website?
The official website for PolarityTE is polarityte.com.
-
Where are PolarityTE's headquarters?
PolarityTE is headquartered at 1960 South 4250 West, Salt Lake City, UT.
-
How can i contact PolarityTE?
PolarityTE's mailing address is 1960 South 4250 West, Salt Lake City, UT and company can be reached via phone at +800 5603983.
PolarityTE company profile:
PolarityTE, Inc.
polarityte.comExchange:
NASDAQ
Full time employees:
42
Industry:
Biotechnology
Sector:
Healthcare
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
1960 South 4250 West
Salt Lake City, UT 84104
Salt Lake City, UT 84104
CIK: 0001076682
ISIN: US7310942070
CUSIP: 731094207
